1. Global initiative for Asthma. Global Strategy for Asthma Management and Prevention [Internet]. [cited 2018 Jul 6]. Available from: https://ginasthma.org/2018-gina-reportglobal-strategy-for-asthma-management-and-prevention/ .
2. Reddel HK, Beckert L, Moran A, Ingham T, Ampon RD, Peters MJ, et al. Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia. Respirology [Internet]. John Wiley & Sons, Ltd; 2017 [cited 2017 Oct 29];22:1570–8. Available from: http://doi.wiley.com/10.1111/resp.13123
3. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma [Internet]. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
4. Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SPC) - (eMC) [Internet]. [cited 2017 Nov 5]. Available from: https://www.medicines.org.uk/emc/medicine/28496
5. Braithwaite I, Williams M, Power S, Pilcher J, Weatherall M, Baines A, et al. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma. Respir Med [Internet]. Elsevier Ltd; 2016;119:115–21. Available from: https://doi.org/10.1016/j.rmed.2016.09.006